Compare SNBR & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNBR | ACET |
|---|---|---|
| Founded | 1987 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.7M | 77.3M |
| IPO Year | 1998 | 2017 |
| Metric | SNBR | ACET |
|---|---|---|
| Price | $1.60 | $7.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $4.50 | ★ $48.33 |
| AVG Volume (30 Days) | ★ 3.4M | 84.7K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,411,450,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.96 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.06 | $0.46 |
| 52 Week High | $13.94 | $9.05 |
| Indicator | SNBR | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 35.55 | 47.05 |
| Support Level | $1.06 | $7.50 |
| Resistance Level | $2.91 | $8.68 |
| Average True Range (ATR) | 0.49 | 0.53 |
| MACD | -0.09 | -0.07 |
| Stochastic Oscillator | 3.83 | 24.22 |
Sleep Number Corp is a designer, manufacturer, marketer, and retailer, which allows it to offer consumers high-quality, individualized sleep solutions and services. It also offers FlextFit adjustable bases, and Sleep Number pillows, sheets, and other bedding products. The company generates revenue by marketing its innovations directly to new and existing customers and selling products through its Stores, Online, Phone, Chat (Total Retail), and Other. It focuses on personalized sleep wellness, with mattresses designed to evolve with each sleeper to help them feel and perform well, featuring adjustable firmness, pressure-relieving support, and temperature-balancing comfort built into every mattress. Its products include mattresses, bundles, bedding, pillows, and furniture.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).